Rationale. Surgery is the only cure for GIST. Tyrosine kinase inhibitors (TKIs) often achieve long-term tumor shrinkage and disease control in KIT- and PDGFRA-mutated GIST, but do not eradicate it. The surviving cells are the source of relapse and resistance. A radioligand kills by radiation-induced DNA damage, independent of KIT/PDGFRA signaling, genotype and resistance mutations. It needs only a target on, or next to, the surviving cell. KIT inhibition also has an impact on DNA-damage repair, which could be potentiated by a radionuclide or an antibody-drug conjugate.
Therapeutic concept. The TKI reduces tumor volume; a radioligand then irradiates the residual cells. Two settings: additive to TKI in metastatic GIST at best response, where residual lesions are still PET-visible; and adjuvant around surgery (high-risk, rupture, metastasectomy), where residual disease is microscopic. The models are radioiodine after thyroidectomy, radioimmunotherapy consolidation in lymphoma and MIBG consolidation in neuroblastoma. Radionuclide therapy works best at low tumor burden.
The question. The design of such a trial depends on a question that is currently unanswered: are the candidate targets present in a sufficient proportion of patients and lesions, and how does TKI treatment alter their expression? Because imatinib-treated GIST undergoes stromal and myxoid remodelling, stromal targets in particular may be upregulated on treatment. No study has yet examined this.
Candidate targets. FAP (fibroblasts, in sarcomas also tumor cells), GRPR (tumor cell membrane), B7-H3 (tumor cell membrane and vasculature) and MT1-MMP (tumor and stroma).
Objectives.
- Tissue mapping. Expression of FAP, B7-H3, GRPR and MT1-MMP in relation to genotype, TKI treatment and treatment duration, by immunohistochemistry and RNA analysis of existing HUSARC and reGISTTry samples, enriched for paired pre- and post-TKI specimens from SURGISTT 2
- PET imaging. Target expression in vivo at baseline, under TKI treatment and by genotype, with available tracers, assessing uptake intensity and heterogeneity between lesions
- Tumor microenvironment. The GIST microenvironment and its remodeling under TKI treatment, by multiplex immunofluorescence, related to target expression
Decision rule. A target supports a radioligand arm in the platform trial only if a clear majority of patients have target-positive residual disease on TKI, contrast against liver, bowel and kidney is workable, and expression holds or rises under TKI. A tumor-cell target that is membranous and retained additionally justifies an adjuvant concept; a purely stromal target supports the metastatic setting only. A negative result is published.
Open for input. Sites with an interest in radioligand or antibody-drug conjugate targets in GIST are invited to comment on the concept and to take part, for example with tissue, PET imaging data or tracers.